ライフサイエンスコーパス: black-box warning

1 he Food and Drug Administration has issued a black box warning advising practitioners to consider alt

2 the US Food and Drug Administration issued a black box warning against TCI use, citing data from case

3 pression, and in 2005, the agency mandated a black box warning and medication guide indicating that p

4 Forty-five drugs (8.2%) acquired 1 or more black box warnings and 16 (2.9%) were withdrawn from the

5 Of these drugs, 22% have black box warnings and 42% list contraindications.

6 hilic species is responsible for over 60% of black box warnings and drug withdrawals from the market

7 ostic testing, the current status of the ECA Black Box Warning, and recommended safety precautions du

8 loride, even though it carries the same FDA "black box" warning as the selective serotonin reuptake i

9 te drug safety and to examine the droperidol black-box warning as a case study.

10 es Food and Drug Administration has issued a black box warning asking providers to use caution when p

11 All nucleoside analogs have a "Black Box" warning because of their potential for inhibi

12 were withdrawn from marketing or received a black-box warning because of hepatotoxicity were prescri

13 avior, and in October 2004, the FDA issued a black box warning concerning all antidepressants for you

14 A black box warning describes a potential risk of malignan

15 t United States Food and Drug Administration black box warning detailed the harmfulness of dronedaron

16 A black box warning for EPO therapy and concerns about neg

17 The black box warning for the use of maintenance ASA doses >

18 Food and Drug Administration issued a black box warning for varenicline regarding neuropsychia

19 d Drug Administration (FDA) announced a new "black box" warning for the perflutren-containing ultraso

20 ies report that there is no basis to issue a black-box warning for perioperative administration of dr

21 treatment of adolescent depression, and the black box warning from the United States Food and Drug A

22 s but prolongs the QT interval and carries a black-box warning from the US Food and Drug Administrati

23 Black-box warnings, generic availability of atorvastatin

24 The paroxetine and black box warnings had modest and relatively targeted ef

25 ns and a Food and Drug Administration-issued black box warning have limited its clinical use.

26 The association is highlighted by a black-box warning issued by the US Food and Drug Adminis

27 ing (June 20, 2003 to October 15, 2004), and black box warning (October 16, 2004 to December 31, 2005

28 to 27.8), more likely to carry a subsequent black-box warning (odds ratio, 4.4; 95% CI, 1.2 to 20.5)

29 ion has been correlated to the addition of a black box warning on a drug label.

30 and suicidality but voted against placing a black box warning on AEDs for suicidality.

31 d and Drug Administration recently placed a "black box" warning on the ultrasound contrast agents Def

32 While the atypical antipsychotics have a 'black box warning' on risk of death in elderly patients

33 The controversy over the 'black box warning' on the use of droperidol is discussed

34 the estimated probability of acquiring a new black box warning or being withdrawn from the market ove

35 oved in 1975-1999; 56 (10.2%) acquired a new black box warning or were withdrawn.

36 occurred including the addition of 1 or more black box warnings per drug, or drug withdrawal.

37 = .85), and more sharply declined during the black box warning period (rate, -0.27; 95% CI, -0.36 to

38 In the black box warning period, there was a small but signific

39 for all 3 antipsychotics declined during the black box warning period.

40 significant difference between the early and black box warning periods (P = .006).

41 t United States Food and Drug Administration black box warning, physicians in the Medicare Advantage

42 equired a change in labeling that included a black box warning regarding SSRI use for all age groups.

43 advisory committee recommended that the 2004 black box warning regarding suicidality in pediatric pat

44 a, the Food and Drug Administration issued a black box warning regarding the risks of rare but seriou

45 However, these agents carry a black box warning regarding their use during pregnancy d

46 Two FDA black box warnings released in August 2013 and July 2016

47 Although the FDA black box warning states that Cryptococcus spp. do not m

48 per year (P = .21) during the paroxetine and black box warning study periods, respectively.

49 ates Food and Drug Administration use of the black-box warning system to promote drug safety and to e

50 eting safety problems (e.g., withdrawals and black-box warnings) than drugs approved at other times.

51 Following the black box warning, the decline continued (rate, -0.26%;

52 nt, has a Food and Drug Administration (FDA) black box warning to avoid maintenance doses of aspirin

53 nd Drug Administration subjectively issued a black-box warning to droperidol, which effectively remov

54 Postapproval, black box warnings were added to labels for four oncolog